Quantcast

Latest C-Met Stories

2009-03-17 07:00:00

INDIANAPOLIS, March 17 /PRNewswire/ -- Semafore Pharmaceuticals, Inc.

2008-10-23 09:00:38

Exelixis, a development-stage biotechnology company, has reported positive interim data from a Phase I dose-escalation trial of XL765, a small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

2008-10-22 09:00:42

MethylGene Inc. (TSX: MYG) today disclosed preclinical biomarker data for its kinase inhibitor, MGCD265, in a poster session at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva.

2008-10-22 06:00:08

Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL765, a novel small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

2008-10-22 06:00:08

Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL147, a novel small molecule inhibitor of phosphoinositide-3 kinase (PI3K), which is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

2008-09-24 12:00:37

Aveo Pharmaceuticals has initiated a Phase I clinical trial to evaluate the safety, tolerability and recommended dose of SCH900105, its novel, highly potent antibody to hepatocyte growth factor, administered intravenously in patients with relapsed or refractory solid tumors or lymphoma.

2008-09-23 06:00:11

AVEO Pharmaceuticals, Inc., today announced that it has initiated a Phase 1 clinical trial to evaluate the safety, tolerability and recommended dose of SCH900105 (AV-299), its novel, highly potent antibody to hepatocyte growth factor (HGF), administered intravenously in patients with relapsed or refractory solid tumors or lymphoma.

2008-09-23 03:00:27

Epistem plc (LSE: EHP), the UK biotechnology and contract research company, will present preclinical results from its recently completed plucked hair biomarker study at the American Association for Cancer Research (AACR) conference, "Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine" in Philadelphia on 23rd September 2008.

2008-08-28 12:01:22

US-based drug discovery company Semafore Pharmaceuticals has announced the discovery of novel multi-targeted kinase inhibitors that demonstrated significant anticancer activity in preclinical studies.

2008-08-07 09:00:14

DUBLIN, Calif., Aug. 7 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that the U.S.


Word of the Day
gubbings
  • The parings of haberdine; also, any kind of fragments.
The word 'gubbings' is a variant of the word 'gobbon', meaning 'a portion, gobbet.'